AZN Jan 2025 72.500 call
| Previous Close | 8.61 |
| Open | 8.61 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 72.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 8.61 - 8.61 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
ReutersFTSE 100 extends record streak on company news
(Reuters) -Britain's FTSE 100 extended its record rally for the fifth straight session on Monday, helped by positive corporate updates, while a stronger pound boosted midcaps. The mid-cap FTSE 250 advanced 1.3%, after touching highest levels in over thirteen months, and taking support from a rise in pound as the currency reached its highest in around two weeks against the dollar. FTSE 100 stocks move in an inverse relationship to the currency, earning their revenues in dollars while reporting profits in sterling, but they were supported by positive company news.
Simply Wall St.AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
As you might know, AstraZeneca PLC ( LON:AZN ) just kicked off its latest quarterly results with some very strong...
